Related Experiment Video

Updated: Jun 22, 2026

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
09:44

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans

Chia-Geun Chen1, Yun-Liang Yang, Kuo-Yun Tseng

  • 1Institute of Preventive Medicine, National Defense Medical Center, Taiwan, ROC.

Fungal Genetics and Biology : FG & B
|June 17, 2009
PubMed

Insights

A newly discovered gene, Regulator of Efflux Pump 1 (REP1), controls drug resistance in Candida albicans. Loss of REP1 increases resistance by boosting the MDR1 efflux pump, impacting antifungal drug efficacy.

Area of Science:

  • Mycology
  • Molecular Biology
  • Antimicrobial Resistance

Background:

  • The MDR1 efflux pump is a key factor in antifungal drug resistance in Candida albicans.
  • Understanding the regulation of MDR1 is crucial for developing effective antifungal therapies.

Purpose of the Study:

  • To identify and characterize novel regulators of the MDR1 efflux pump in Candida albicans.
  • To elucidate the role of Regulator of Efflux Pump 1 (REP1) in mediating antifungal drug resistance.

Main Methods:

  • Gene expression analysis in Saccharomyces cerevisiae and Candida albicans.
  • Phenotypic screening of drug susceptibility in yeast strains.
  • Quantitative analysis of MDR1 mRNA levels.

Main Results:

  • Overexpression of REP1 in Saccharomyces cerevisiae led to increased susceptibility to fluconazole.
  • Null mutations in REP1 in Candida albicans resulted in decreased susceptibility to antifungal drugs.
  • REP1 null mutants exhibited significantly increased MDR1 mRNA expression.

Conclusions:

  • Regulator of Efflux Pump 1 (REP1) acts as a negative regulator of the MDR1 efflux pump in Candida albicans.
  • REP1 plays a critical role in modulating antifungal drug resistance by controlling MDR1 expression.
  • Targeting REP1 could be a potential strategy to overcome drug resistance in Candida albicans infections.

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...